

????????????????????

????



Randomized Controlled Trial,

RCT


??????

Response Rate, ORR

Overall Survival, OS
Progression Free Survival, PFS


Objective

???????OS?



OS
OS

ITT



OS
log-rank
Cox
Kaplan-Meier
log-rank
log-rank

The diagram illustrates a 16-bit bus architecture. It features a central horizontal bus line. Above the bus, there are two main blocks: 'BSC' (Base Station Controller) on the left and 'SOC' (System On Chip) on the right. Below the bus, there are two main blocks: 'OS' (Operating System) on the left and 'PFS' (Power/Frequency Scaling) on the right. The bus is connected to various components, including a 'PFS' block on the left, an 'OS' block on the right, and a 'BSC' block at the bottom. The bus is labeled '16-bit' on the left side. The diagram shows the flow of data and control signals between these components.

??????

ICH E9

1. ??????

[illegible]

2. ????????

[illegible]



??????

1. Bretz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective multiple test procedures[J]. *Statistics in medicine*, 2009, 28(4): 586-604.
2. Chapman P B, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. *New England Journal of Medicine*, 2011, 364(26): 2507-2516.
3. Chen C, Li X N, Li W, et al. Adaptive expansion of biomarker populations in phase 3 clinical trials[J]. *Contemporary clinical trials*, 2018, 71: 181-185.
4. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients[J]. *Clinical cancer research*, 2005, 11(21): 7872-7878.
5. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial[J]. *Clinical trials*, 2006, 3(1): 57-71.
6. Hobbs B P, Barata P C, Kanjanapan Y, et al. Seamless designs: current practice and considerations for early-phase drug development in oncology[J]. *JNCI: Journal of the National Cancer Institute*, 2019, 111(2): 118-128.
7. Howard D R, Brown J M, Todd S, et al. Recommendations on multiple testing adjustment in multi-arm trials with a shared control group[J]. *Statistical methods in medical research*, 2018, 27(5): 1513-1530.
8. ICH. E9(R1) Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2019.
9. Ji Y, Liu P, Li Y, et al. A modified toxicity probability interval method for dose-finding trials[J]. *Clinical trials*, 2010, 7(6): 653-663.
10. Kang S P, Gergich K, Lubiniecki G M, et al. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic[J]. *Annals of oncology*, 2017, 28(6): 1388-1398.
11. Mandrekar S J, Sargent D J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges[J]. *Journal of clinical oncology*, 2009, 27(24): 4027.
12. Mayawala K, Tse A, Rubin E H, et al. Dose finding versus speed in seamless immune-oncology drug development[J]. *The journal of clinical pharmacology*, 2017, 57: S143-S145.
13. Proschan M A, Follmann D A. Multiple comparisons with control in a single experiment versus separate experiments: why do we feel differently?[J]. *The american statistician*, 1995, 49(2): 144-

14. Schwartz L H, Litière S, de Vries E, et al. RECIST 1.1—update and clarification: from the RECIST committee[J]. European journal of cancer, 2016, 62: 132-137.

15. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. The lancet oncology, 2017, 18(3): e143-e152.

16. Sun L Z, Kang S P, Chen C. Testing monotherapy and combination therapy in one trial with biomarker consideration[J]. Contemporary clinical trials, 2019, 82: 53-59.

17. Yuan Y, Hess K R, Hilsenbeck S G, et al. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials[J]. Clinical cancer research, 2016, 22(17): 4291-4301.

18. Zhou H, Yuan Y, Nie L. Accuracy, safety, and reliability of novel phase I trial design[J]. Clinical cancer research, 2018, 24(18): 4357-4364

??????????

□□	□□
□□□□□□□□	Blinded Independent Central Review, BICR
□□□□	Partial Response, PR
□□□□□	Patient Reported Outcome, PRO
□□□□□□	Institutional Review Board, IRB
□□□□□	Disease Control Rate, DCR
□□□□□	Objective Response Rate, ORR
□□□□	First in Human, FIH
□□ □□□□	Recommended Phase 2 Dose, RP2D
□□□□	Complete Response, CR
□□□□□	Disease Free Survival, DFS
□□□□□□	Progression Free Survival, PFS
□□□□□□	Event Free Survival, EFS
□□□□□□□	Time to Progression, TTP
□□□□□□□□	Time to Failure, TTF
□□□□	Overall Survival, OS
□□□□□□	Best Supportive Care, BSC